智飞生物(300122) - 2020 Q4 - 年度财报

Section 1 Important Notice, Table of Contents, and Definitions This section provides crucial disclaimers, outlines the report structure, and defines key terminology for clarity Important Notice The company's board and management guarantee report accuracy, cautioning investors on product R&D and sales risks, and disclosing the 2020 profit distribution plan - The company advises investors to pay attention to two core risks: product R&D not meeting expectations and product sales not meeting expectations[3][4] - The company's 2020 profit distribution plan is: based on 1.6 billion shares, a cash dividend of 5 yuan (tax inclusive) will be distributed for every 10 shares[5] Definitions This chapter defines key terms used in the report, including company entities, products, business models, industry terms, and regulatory bodies, providing a foundational understanding Section 2 Company Profile and Key Financial Indicators This section presents the company's fundamental information and a summary of its key financial performance metrics Company Information This chapter provides the company's basic business information, including stock code, legal representative, addresses, contact details, and information disclosure channels - The company's stock abbreviation is "Zhifei Biological", and the stock code is 300122[10] Key Accounting Data and Financial Indicators The company achieved strong 2020 performance with operating revenue reaching 15.19 billion yuan and net profit attributable to parent company at 3.301 billion yuan, alongside significant growth in operating cash flow, total assets, and net assets Key Accounting Data and Financial Indicators | Indicator | 2020 | 2019 | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Operating Revenue (RMB) | 15,190,366,231.21 | 10,587,318,311.60 | 43.48% | | Net Profit Attributable to Shareholders of Listed Company (RMB) | 3,301,326,830.15 | 2,366,438,733.29 | 39.51% | | Net Cash Flow from Operating Activities (RMB) | 3,496,688,940.12 | 1,366,993,830.88 | 155.79% | | Basic Earnings Per Share (RMB/share) | 2.0633 | 1.4790 | 39.51% | | Weighted Average Return on Net Assets | 46.29% | 47.67% | -1.38% | | Total Assets (RMB) | 15,215,241,753.29 | 10,942,422,443.88 | 39.05% | | Net Assets Attributable to Shareholders of Listed Company (RMB) | 8,248,664,459.27 | 5,747,337,629.12 | 43.52% | Quarterly Key Accounting Data | Quarter | Operating Revenue (RMB) | Net Profit Attributable to Shareholders of Listed Company (RMB) | | :--- | :--- | :--- | | Q1 | 2,634,599,232.63 | 516,363,351.01 | | Q2 | 4,359,123,952.00 | 988,185,044.15 | | Q3 | 4,056,063,967.03 | 974,047,337.21 | | Q4 | 4,140,579,079.55 | 822,731,097.78 | - During the reporting period, the company's total non-recurring gains and losses amounted to -21.5786 million yuan, primarily consisting of government subsidies, fair value changes in financial instruments, and other non-operating income and expenses[17][18] Section 3 Business Overview This section outlines the company's core business activities, significant asset changes, and key competitive advantages Main Business Activities During the Reporting Period The company is a bio-high-tech enterprise integrating vaccine R&D, production, sales, and import/export, operating under a 'technology + market' dual-driven model with a nationwide marketing network and a portfolio of proprietary and agency products - The company adopts a 'technology + market' dual-driven model, possessing a marketing network covering 31 provinces nationwide and over 30,000 primary healthcare service points[20] Key Products | Product Category | Trade Name | Purpose | | :--- | :--- | :--- | | Proprietary Products | Mengweike, Mengnakang, Xifeibei, Zhikeweide, Yika, Weika | Prevention of meningococcal meningitis, Haemophilus influenzae type b infection, COVID-19 infection, and tuberculosis diagnosis and adjuvant therapy | | Agency Products (MSD) | Gardasil, Gardasil 9, Rotateq, Pneumovax 23, Vaqta | Prevention of HPV (cervical cancer), rotavirus, pneumococcal, hepatitis A, and other diseases | - The global vaccine market is projected to grow from $32.5 billion in 2019 to $56.1 billion in 2026, indicating significant growth potential[23] Significant Changes in Major Assets During the reporting period, the company's major assets, including accounts receivable, inventory, fixed assets, and development expenditures, significantly increased due to sales growth, increased agency product procurement, project completion, and capitalized R&D investments Major Asset Changes | Major Asset | Period-End vs. Period-Start Growth Rate | Primary Reason | | :--- | :--- | :--- | | Accounts Receivable | 49.30% | Continuous growth in sales revenue | | Inventory | 37.07% | Increased procurement of agency products as planned | | Fixed Assets | 42.76% | Completed construction-in-progress projects transferred to fixed assets | | Development Expenditures | 70.57% | Increased capitalized investment in R&D projects | Core Competitiveness Analysis The company's core competitiveness stems from its industry-leading R&D capabilities, mature nationwide marketing network, and standardized operational management, ensuring product quality and sales performance - The company's R&D investment in 2020 reached 481 million yuan, with 414 R&D personnel and 27 ongoing projects, forming multiple vaccine product matrices for tuberculosis, rabies, pneumonia, and meningitis[26][27] - The company's marketing network covers 31 provinces, over 300 prefectures, over 2,600 districts/counties, and over 30,000 primary healthcare service points nationwide, effectively ensuring product sales[32] - The company has established a strict quality control system, maintaining a 100% batch release qualification rate for proprietary products since their first launch in 2008[33] Section 4 Management Discussion and Analysis This section provides a detailed review of the company's operational performance, product development, and future strategic outlook I. Overview In 2020, the company achieved significant growth despite the pandemic, driven by strong revenue and net profit increases, strategic R&D investments, successful product launches, expanded market promotion, and forward-looking investments in new health technologies - The recombinant COVID-19 vaccine (CHO cell) developed by the company in collaboration with the Institute of Microbiology, Chinese Academy of Sciences, initiated clinical trials in June 2020 and was included in emergency use in March 2021[36] - R&D investment in 2020 reached 481 million yuan, a year-on-year increase of 85.61%, accounting for 40.02% of proprietary product revenue[39] - The company renewed its agency agreement with MSD, further clarifying vaccine product procurement plans until the end of June 2023; as of the end of the reporting period, over 25 million doses of HPV vaccine had been cumulatively released[42] - The company strategically invested in Shenzhen Shenxin Biotechnology Co., Ltd. to establish an mRNA technology platform[44] Product R&D and Batch Release Status As of the reporting period end, the company had 27 proprietary R&D projects with key approvals for EC diagnostic reagent, recombinant COVID-19, and inactivated rotavirus vaccines, while both proprietary and agency vaccine batch releases saw significant increases - The company has a total of 27 proprietary R&D projects, with Mycobacterium bovis vaccine (for tuberculosis-infected population) in the production application stage, and multiple products including 15-valent pneumococcal conjugate vaccine and recombinant COVID-19 vaccine in Phase III clinical trials[46][47] Proprietary Product Batch Release Status | Proprietary Product | 2020 Batch Release Volume (doses) | 2019 Batch Release Volume (doses) | Growth Rate | | :--- | :--- | :--- | :--- | | ACYW Meningococcal Polysaccharide Vaccine | 6,062,370 | 754,797 | 703.18% | | AC Conjugate Vaccine | 4,404,060 | 669,205 | 558.10% | Agency Product Batch Release Status | Agency Product (MSD) | 2020 Batch Release Volume (doses) | 2019 Batch Release Volume (doses) | Growth Rate | | :--- | :--- | :--- | :--- | | Quadrivalent HPV Vaccine | 7,219,462 | 5,543,719 | 30.23% | | Nonavalent HPV Vaccine | 5,066,376 | 3,324,173 | 52.41% | II. Main Business Analysis In 2020, the company's main business revenue reached 15.19 billion yuan, primarily driven by agency non-immunization program vaccines contributing 13.955 billion yuan, with East China as the largest market, and overall sales, production, and inventory volumes increasing significantly Main Business Revenue Composition | Revenue Component | 2020 Revenue (RMB) | Share of Total Revenue | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Agency Products - Non-Immunization Program Vaccines | 13,955,381,554.82 | 91.86% | 51.88% | | Proprietary Products - Non-Immunization Program Vaccines | 1,197,987,988.40 | 7.89% | -9.50% | | Proprietary Products - Therapeutic Biological Products | 2,768,852.43 | 0.02% | -79.05% | Main Business by Region | Region | 2020 Revenue (RMB) | Share of Total Revenue | | :--- | :--- | :--- | | East China | 5,191,826,815.43 | 34.18% | | South China | 2,436,024,991.83 | 16.04% | | Central China | 2,397,183,366.85 | 15.78% | - The top five customers accounted for 8.63% of the company's total annual sales, while the top five suppliers (primarily MSD) accounted for 92.78% of total annual procurement, indicating a high dependency on core suppliers[71][73] - Financial expenses and R&D expenses significantly increased by 75.35% and 76.73% year-on-year respectively, primarily due to increased interest expenses from higher short-term borrowings and increased R&D investments[75] IX. Company's Future Development Outlook The company plans to focus on its core vaccine business while expanding into biopharmaceuticals, advancing its R&D pipeline, ensuring product quality, enhancing market strategies, and optimizing governance, while also addressing identified risks such as policy changes, bad debts, talent management, adverse reactions, and vaccine hesitancy - The company's strategic core is to steadily advance R&D, ensure product clinical and registration processes, and strengthen the construction of Zhirui Biopharmaceutical Industrial Park to expand into therapeutic macromolecular drug fields such as oncology and metabolic diseases[91] - The main risks faced by the company include: changes in industry regulatory policies, accounts receivable bad debt risk due to expanding sales scale, talent management risk from sales team expansion, vaccine adverse reaction risk, and public "vaccine hesitancy" sentiment[93][94][95] Section 5 Significant Matters This section details the company's profit distribution plan, significant contracts, and employee stock ownership plan Profit Distribution and Capital Reserve Conversion to Share Capital The company's 2020 profit distribution plan proposes a cash dividend of 5 yuan per 10 shares based on 1.6 billion shares, totaling 800 million yuan, representing 24.23% of net profit attributable to the parent company, consistent with prior years Cash Dividends for the Past Three Years | Dividend Year | Cash Dividend Amount (RMB) | Ratio of Net Profit Attributable to Ordinary Shareholders of Listed Company in Consolidated Financial Statements | | :--- | :--- | :--- | | 2020 | 800,000,000.00 | 24.23% | | 2019 | 800,000,000.00 | 33.81% | | 2018 | 800,000,000.00 | 55.12% | Significant Contracts and Their Performance During the reporting period, the company's significant contracts with MSD were performed normally, with HPV vaccine procurement reaching 8.33 billion yuan in 2020, and a new agreement signed in December 2020 to adjust and renew procurement for five agency products - On December 22, 2020, the company signed a new agreement with MSD, renewing and adjusting the basic procurement amounts for HPV vaccine, pentavalent rotavirus vaccine, 23-valent pneumococcal vaccine, and inactivated hepatitis A vaccine[119] Employee Stock Ownership Plan The company's second employee stock ownership plan completed stock purchases in 2019, acquiring 16,150,000 shares at an average price of 41.2753 yuan/share, with its lock-up period expiring on July 29, 2020, and 8,901,164 shares still held as of the reporting period end - The lock-up period for the company's second phase employee stock ownership plan expired on July 29, 2020, and as of the end of the reporting period, the plan still held 8,901,164 shares[114] Section 6 Share Changes and Shareholder Information This section details changes in the company's share capital and provides an overview of its shareholder structure Share Change Status During the reporting period, the company's total share capital remained at 1.6 billion shares, with restricted shares decreasing by 24.6 million shares due to executive lock-up share unlocking, shifting the proportion of restricted to unrestricted shares - During the reporting period, the company's total share capital of 1,600,000,000 shares remained unchanged, with share changes primarily due to the annual unlocking of executive restricted shares[128] Shareholders and Actual Controller Information As of the reporting period end, the company had 94,851 shareholders, with Mr. Jiang Rensheng as the controlling shareholder holding 50.35%, and Hong Kong Securities Clearing Company Limited as the fourth largest shareholder with 3.23% - The company's controlling shareholder and actual controller is Jiang Rensheng, with a shareholding ratio of 50.35% at the end of the reporting period[134][140] Top Ten Shareholders' Shareholding | Shareholder Name | Shareholding Percentage | Number of Shares Held at Period End | | :--- | :--- | :--- | | Jiang Rensheng | 50.35% | 805,520,000 | | Jiang Lingfeng | 5.40% | 86,400,000 | | Liu Tieying | 3.81% | 61,000,000 | | Hong Kong Securities Clearing Company Limited | 3.23% | 51,624,330 | | Wu Guanjiang | 3.02% | 48,280,000 | Section 9 Directors, Supervisors, Senior Management, and Employees This section provides details on the shareholding changes and remuneration of the company's directors, supervisors, and senior management, as well as overall employee information Changes in Shareholdings of Directors, Supervisors, and Senior Management During the reporting period, Chairman Jiang Rensheng reduced his shareholding by 27,720,000 shares and Deputy General Manager Jiang Xisheng by 1,000,000 shares, while the total remuneration paid to the 18 directors, supervisors, and senior management in 2020 was 12.9265 million yuan - Chairman Jiang Rensheng reduced his shareholding by 27,720,000 shares during the reporting period, with his shareholding at period-end being 805,520,000 shares[145] - The company has a total of 18 directors, supervisors, and senior management, with the total actual remuneration paid in 2020 amounting to 12.9265 million yuan[154][155][156] Company Employee Information As of the reporting period end, the company had 3,380 employees, with sales personnel comprising the largest group at 1,905, and over 70% of employees holding a bachelor's degree or higher, indicating high personnel quality Employee Professional Composition | Professional Composition | Number of Employees | | :--- | :--- | | Production Personnel | 763 | | Sales Personnel | 1,905 | | Technical Personnel | 414 | | Financial Personnel | 62 | | Administrative Personnel | 236 | | Total | 3,380 | Section 10 Corporate Governance This section provides an overview of the company's corporate governance structure and its adherence to regulatory standards Basic Status of Corporate Governance The company maintains a compliant and independent corporate governance structure with clear responsibilities, effective checks and balances, and active board and supervisory committee functions, including performance-linked executive incentives, ensuring legal operations and financial integrity - The actual status of the company's corporate governance complies with the requirements of normative documents such as the 'Guidelines for Corporate Governance of Listed Companies', with no significant discrepancies[161][162] - The company maintains independence from its controlling shareholder in terms of business, personnel, assets, organization, and finance, possessing independent and complete business operations and autonomous management capabilities[163][164][165][166] - The four special committees under the company's board of directors—Audit, Nomination, Remuneration and Appraisal, and Strategy—all performed their duties normally during the reporting period[171] Section 12 Financial Report This section presents the company's audited financial statements and key consolidated financial data I. Audit Report ShineWing Certified Public Accountants issued a standard unqualified audit opinion on the company's 2020 financial statements, confirming fair presentation in accordance with accounting standards, with key audit matters focusing on inventory impairment, accounts receivable bad debt provisions, and revenue recognition - The auditing firm is ShineWing Certified Public Accountants (Special General Partnership), which issued a standard unqualified audit opinion[188][189] - Key audit matters include: - Inventory impairment provisions: Due to high book value of inventory (accounting for 22.38% of total assets) and significant increase - Accounts receivable bad debt provisions: Due to high accounts receivable balance (accounting for 43.54% of total assets), bad debt risk has a significant impact on the financial statements - Revenue recognition: Due to operating revenue being a key performance indicator and increasing by 43.48% year-on-year, there is an inherent risk of management manipulating revenue recognition timing[191][192] Key Consolidated Financial Statement Data As of 2020 year-end, the company reported 15.215 billion yuan in total assets, 6.967 billion yuan in total liabilities, and 8.249 billion yuan in equity attributable to the parent, with 15.19 billion yuan in operating revenue and 3.301 billion yuan in net profit for the year Key Consolidated Balance Sheet Data | Balance Sheet Item (Consolidated) | 2020 Year-End (RMB) | 2019 Year-End (RMB) | | :--- | :--- | :--- | | Total Assets | 15,215,241,753.29 | 10,942,422,443.88 | | Total Liabilities | 6,966,577,294.02 | 5,195,084,814.76 | | Equity Attributable to Parent Company Owners | 8,248,664,459.27 | 5,747,337,629.12 | Key Consolidated Income Statement Data | Income Statement Item (Consolidated) | 2020 Annual (RMB) | 2019 Annual (RMB) | | :--- | :--- | :--- | | Total Operating Revenue | 15,190,366,231.21 | 10,587,318,311.60 | | Total Operating Costs | 11,179,799,938.20 | 7,709,979,663.15 | | Net Profit | 3,301,326,830.15 | 2,366,438,733.29 | Key Consolidated Cash Flow Statement Data | Cash Flow Statement Item (Consolidated) | 2020 Annual (RMB) | 2019 Annual (RMB) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 3,496,688,940.12 | 1,366,993,830.88 | | Net Cash Flow from Investing Activities | -896,881,545.26 | -622,733,368.64 | | Net Cash Flow from Financing Activities | -2,113,588,340.56 | -392,796,755.93 |